Volume 35 Number 11 September 10-17, 2015
Cancer
Availability and payer coverage of BRCA1/2 tests and gene panels.
Clain E et al. Nat. Biotechnol. 2015 Sep 8. 33(9) 900-902
Clain E et al. Nat. Biotechnol. 2015 Sep 8. 33(9) 900-902
BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study
Høberg-Vetti H, et al. European Journal of Human Genetics 2015 Sep 9
Høberg-Vetti H, et al. European Journal of Human Genetics 2015 Sep 9
Colonoscopy screening among US adults aged 40 or older with a family history of colorectal cancer.
Tsai Meng-Han et al. Prev Chronic Dis 2015 12E80
Tsai Meng-Han et al. Prev Chronic Dis 2015 12E80
Cost-effectiveness of universal BRCA1/2 screening: evidence-based decision making.
Long EF et al. JAMA Oncol 2015 Sep 3. 1-2
Long EF et al. JAMA Oncol 2015 Sep 3. 1-2
Health professionals' opinions on supporting a cancer biobank: identification of barriers to combat biobanking pitfalls.
Caixeiro NJ et al. Eur. J. Hum. Genet. 2015 Sep 2.
Caixeiro NJ et al. Eur. J. Hum. Genet. 2015 Sep 2.
Molecular testing for treatment of metastatic non-small cell lung cancer: How to implement evidence-based recommendations.
Levy BP et al. Oncologist 2015 Sep 1.
Levy BP et al. Oncologist 2015 Sep 1.
Oncotype DX in bilateral synchronous primary invasive breast cancer.
Karsten M et al. Ann. Surg. Oncol. 2015 Sep 4.
Karsten M et al. Ann. Surg. Oncol. 2015 Sep 4.
Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice guideline update.
Masters GA et al. J. Clin. Oncol. 2015 Aug 31.
Masters GA et al. J. Clin. Oncol. 2015 Aug 31.
The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.
Normanno N et al. J Transl Med 2015 13287
Normanno N et al. J Transl Med 2015 13287
.png)
No hay comentarios:
Publicar un comentario